John Northcott is CCO & VP at NEKTAR THERAPEUTICS (NKTR). They have made 6 open-market trades across 1 company since 2021, most recently 2022-05-16.
CIK 0001615000
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTR | SELL | 2022-05-16 | 2022-05-17 | $3.95 | $18K | -7.6% | -15.4% | +28.2% |
| NKTR | SELL | 2022-02-16 | 2022-02-18 | $10.95 | $106K | +2.4% | -45.0% | -62.2% |
| NKTR | SELL | 2021-11-16 | 2021-11-17 | $13.16 | $160K | -11.4% | +7.6% | -12.0% |
| NKTR | SELL | 2021-08-16 | 2021-08-18 | $13.83 | $171K | +12.9% | +23.0% | -1.0% |
| NKTR | SELL | 2021-05-17 | 2021-05-19 | $18.30 | $223K | -0.6% | -6.5% | -24.8% |
| NKTR | SELL | 2021-02-16 | 2021-02-18 | $22.37 | $687K | -5.0% | -10.5% | -26.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.